Ongoing Phase 3 Trials: Liver Disease Agonists π
Ongoing Phase 3 Trials: Liver Disease Agonists π
Created using ChatSlide
Explore the frontiers of liver disease treatment with our latest findings from Phase 3 trials focusing on agonists. Dive into the specifics of two pivotal trials: Tirzepatide for MASH, highlighting its mild gastrointestinal side effects with weekly doses; and Resmetirom for NASH, showcasing a comparable safety profile with daily doses. Through a comparative analysis, assess the efficacy, safety profiles, and impacts on cholesterol and fibrosis. Understand the broader therapeutic implications...